Fulgent Genetics, Inc.

NasdaqGM:FLGT 주식 보고서

시가총액: US$547.2m

Fulgent Genetics 관리

관리 기준 확인 2/4

Fulgent Genetics CEO는 Ming Hsieh, May2016 에 임명되었습니다 의 임기는 8.5 년입니다. 총 연간 보상은 $ 5.31M, 18.8% 로 구성됩니다. 18.8% 급여 및 81.2% 보너스(회사 주식 및 옵션 포함). 는 $ 156.09M 가치에 해당하는 회사 주식의 28.52% 직접 소유합니다. 156.09M. 경영진과 이사회의 평균 재임 기간은 각각 4.7 년과 3.8 년입니다.

주요 정보

Ming Hsieh

최고 경영자

US$5.3m

총 보상

CEO 급여 비율18.8%
CEO 임기8.5yrs
CEO 소유권28.5%
경영진 평균 재임 기간4.7yrs
이사회 평균 재임 기간3.8yrs

최근 관리 업데이트

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10
Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Recent updates

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Sep 25

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

Sep 09

Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Jul 17
Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Fulgent Genetics: Growth Is Returning

Jun 06

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10
Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 07
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Mar 01
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Jan 17
Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Dec 14
Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Aug 09
Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Apr 19
Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Oct 27
Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Wait For Fulgent Genetics To Grow Up

Oct 13

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Sep 19
We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Sep 05
Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Jul 26

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Jul 21
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04
Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Fulgent Is Putting Its Cash Bonanza To Work

May 15

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04
These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Fulgent Genetics: Now The Going Could Get Much Tougher

Apr 10

Fulgent Genetics: COVID Bolstered The Underlying Business

Mar 17

Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business

Feb 27

Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy

Feb 09

Fulgent Genetics: Sell Volatility

Jan 26

CEO 보상 분석

Ming Hsieh 의 보수는 Fulgent Genetics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$165m

Jun 30 2024n/an/a

-US$163m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$5mUS$1m

-US$168m

Sep 30 2023n/an/a

-US$64m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$5mUS$948k

US$143m

Sep 30 2022n/an/a

US$272m

Jun 30 2022n/an/a

US$392m

Mar 31 2022n/an/a

US$461m

Dec 31 2021US$6mUS$664k

US$507m

Sep 30 2021n/an/a

US$569m

Jun 30 2021n/an/a

US$493m

Mar 31 2021n/an/a

US$417m

Dec 31 2020US$248kUS$240k

US$214m

Sep 30 2020n/an/a

US$48m

Jun 30 2020n/an/a

US$3m

Mar 31 2020n/an/a

-US$459k

Dec 31 2019US$240kUS$240k

-US$411k

Sep 30 2019n/an/a

-US$2m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$240kUS$240k

-US$6m

Sep 30 2018n/an/a

-US$5m

Jun 30 2018n/an/a

-US$6m

Mar 31 2018n/an/a

-US$5m

Dec 31 2017US$240kUS$240k

-US$3m

보상 대 시장: Ming 의 총 보상 ($USD 5.31M )은 US 시장( $USD 2.11M ).

보상과 수익: 회사가 수익성이 없는 동안 Ming 의 보상이 증가했습니다.


CEO

Ming Hsieh (68 yo)

8.5yrs

테뉴어

US$5,309,167

보상

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...


리더십 팀

이름위치테뉴어보상소유권
Ming Hsieh
Chairman & CEO8.5yrsUS$5.31m28.52%
$ 156.1m
Jian Xie
COO & President6.6yrsUS$1.79m1.42%
$ 7.8m
Paul Kim
Chief Financial Officer8.8yrsUS$1.78m0.40%
$ 2.2m
Hanlin Gao
Chief Scientific Officer & Laboratory Director8.2yrsUS$1.49m2.8%
$ 15.3m
Natalie Prescott
General Counsel & Chief Privacy Officer2.5yrs데이터 없음데이터 없음
Doreen Ng
VP of Operations & Compliance and GM of Houston Office4.1yrs데이터 없음데이터 없음
Jakub Sram
Vice President of Business Development & Sales9.8yrs데이터 없음데이터 없음
Ellen Tsui
Vice President of Human Resources2.5yrs데이터 없음데이터 없음
Brandon Perthuis
Chief Commercial Officer4.7yrs데이터 없음데이터 없음
Lawrence Weiss
Chief Medical Officer3.5yrs데이터 없음데이터 없음
Ray Yin
President & Chief Scientific Officer of Fulgent Pharma2yrs데이터 없음데이터 없음

4.7yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: FLGT 의 관리팀은 경험 ( 4.7 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Ming Hsieh
Chairman & CEO8.5yrsUS$5.31m28.52%
$ 156.1m
Regina Groves
Independent Non-Employee Director1.8yrsUS$625.60k0.0039%
$ 21.2k
Linda Marsh
Independent Director5.3yrsUS$270.50k0.061%
$ 333.8k
Michael Nohaile
Independent Non-Employee Director2.3yrsUS$268.50k0.0078%
$ 42.6k

3.8yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: FLGT 의 이사회경험(평균 재직 기간 3.8 년)으로 간주됩니다.